Fewer than a tenth of patients who could benefit from weight-loss injections such as Wegovy have access to them, caution the World Health Organization as it issues its first advice on the therapies.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
Per forecasts, over two billion could be obese by 2030 unless action is taken.
"The latest guidance recognises that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major obstacles to broad access to the injections that can assist patients in reducing significant body mass, explains the agency.
Skinny Jab Supply Crisis
Even in the present most optimistic scenario, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, per the WHO.
The recommendation urges countries and companies to increase availability, via measures including patent sharing.
A patent on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Jabs Function
These medications mimick a biological compound to slow digestion, suppress the appetite and increase feelings of fullness so individuals reduce food intake.
Individuals usually start to lose weight within a few weeks of beginning the once-weekly jabs.
Studies indicates people may see weight return after a year of stopping the medication, when their usual appetite resume.
To be carrying excess weight increases your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in every country and was associated with millions of fatalities worldwide in 2024, per the WHO.
